A pancreatic cancer pill looks striking—but the evidence is still early

Daraxonrasib plus chemotherapy controlled tumors in most patients in a small early trial, prompting striking hopes. But without a comparison group, researchers cannot yet show whether it extends survival.
A pancreatic cancer pill looks striking—but the evidence is still early

A pancreatic cancer pill looks striking—but the evidence is still early
An experimental drug combination has produced unusually strong early results against advanced pancreatic cancer, but the numbers that have stirred hope come from a small trial that cannot yet establish whether the treatment is better than chemotherapy alone.

In the 61-patient study, daraxonrasib, a daily pill, was given with two standard chemotherapy drugs. Tumors shrank in 60.7% of patients, disappearing on scans in 8.2%; growth was halted in 90.2%. Median time before the cancer worsened was 12.8 months, and 76.6% of participants were alive at one year. The findings were presented at a cancer conference in Barcelona.

The more celebratory account casts the results as a rare breakthrough for a disease with a grim prognosis. It reports that one-year survival is typically 40–45% with chemotherapy alone, and quotes study lead Dr. Wungki Park calling the response “the closest to cure.” Yet the same report notes doctors cannot call the pill a cure or say how long the disease may remain controlled. Cancer Research UK chief executive Michelle Mitchell called the findings “the biggest leap forward we’ve seen in decades,” while stressing that further trials are needed before the treatment can be assessed for use in the UK’s NHS.

The more cautious framing focuses on what the study cannot show: all participants received the drug combination, so there was no group taking chemotherapy alone for direct comparison. Researchers also have not established that the regimen extends overall survival. Side effects included rash, diarrhea, fatigue and low blood-cell counts; 5% stopped treatment because of effects linked to daraxonrasib.

Both accounts point to the drug’s effort to block RAS-driven tumor growth, a mechanism relevant to many pancreatic cancers. But the trial’s results apply only to metastatic pancreatic cancer, and claims about other cancers remain speculative. A larger randomized phase 3 study is now comparing the drug, alone and with chemotherapy, against chemotherapy alone.

Write a comment